An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review

References

• Andrews G, Carter GL. 2001. What people say about their general practitioners’ treatment of anxiety and depression. Med J Aust 175:S48–S51.
   PubMed Web of Science ®Google Scholar
• Aoshima H, Hamamoto K. 1999. Potentiation of GABAA receptors expressed in Xenopus oocytes by perfume and phytoncid. Biosci Biotechnol Biochem 63:743–748.
   PubMed Web of Science ®Google Scholar
• Binder G, König WA. 2000. Ätherische Öle – Untersuchung zur Deklaration und Qualität ausgewählter Präparate. Deutsche Apotheker Zeitung 140:4205–4210.
   Google Scholar
• Buffett-Jerrott SE, Stewart SH. 2002. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 8:45–58.
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. 1989. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213.
   PubMed Web of Science ®Google Scholar
• Cavanagh HM, Wilkinson JM. 2002. Biological activities of lavender essential oil. Phytother Res 16:301–308.
   PubMed Web of Science ®Google Scholar
• Hamilton M. 1976. Hamilton Anxiety Scale (HAMA). In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch, pp. 193–197.
   Google Scholar
• Hoogland HJ, Skouby SO. 1993. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 47:583–590.
   PubMed Web of Science ®Google Scholar
• Iguchi MY, Handelsman L, Bickel WK, Griffiths RR. 1993. Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend 32:257–266.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. 1996. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12.
   PubMedGoogle Scholar
• Kasper S, Anghelescu I, Dienel A. 2010a. Efficacy of Silexan (WS® 1265) in Patients with Restlessness and Sleep Disturbance. Annual Congress of the German Society for Psychiatry and Psychotherapy (DGPPN). Berlin, Germany.
   Google Scholar
• Kasper S, Dienel A. 2011. Effects of Silexan® on human cytochrome P450 activity and contraceptive efficacy of a combined oral contraceptive. Annual Congress of the German Society for Psychiatry and Psychotherapy (DGPPN). Berlin, Germany.
   Google Scholar
• Kasper S, Gastpar M, Muller WE, Volz HP, Moller HJ, Dienel A, Schlafke S. 2010b. Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials. Wien Med Wochenschr 160:547–556.
   PubMedGoogle Scholar
• Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Dienel A, Schläfke S. 2010c. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol 25:277–287.
   PubMed Web of Science ®Google Scholar
• Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Schläfke S, Dienel A. 2011. No withdrawal symptoms after discontinuation of Silexan®. Annual Congress of the German Society for Psychiatry and Psychotherapy (DGPPN). Berlin, Germany.
   Google Scholar
• Kendall PC, Finch AJ Jr, Auerbach SM, Hooke JF, Mikulka PJ. 1976. The State-Trait Anxiety Inventory: a systematic evaluation. J Consult Clin Psychol 44:406–412.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Brandenburg N, Lane M, Roy-Byrne P, Stang PD, Stein DJ, Wittchen HU. 2005. Rethinking the duration require ment for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med 35: 1073–1082.
   PubMed Web of Science ®Google Scholar
• Lader MH. 1999. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 9:S399–S405.
   PubMed Web of Science ®Google Scholar
• Lewinsohn PM, Shankman SA, Gau JM, Klein DN. 2004. The prevalence and co-morbidity of subthreshold psychiatric conditions. Psychol Med 34:613–622.
   PubMed Web of Science ®Google Scholar
• Longo LP, Johnson B. 2000. Addiction: Part I. Benzodiazepines– side effects, abuse risk and alternatives.Am Fam Physician 61: 2121–2128.
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. 1970. 12 - CGI. Clinical Global Impressions. In: Guy W, editor. EDCEU Assessment in Psychopharmacology. Rockville, MD: U.S. National Institute of Mental Health, Psychopharmacology Research Branch, pp. 217–222.
   Google Scholar
• Onyett SR. 1989. The benzodiazepine withdrawal syndrome and its management. J R Coll Gen Pract 39:160–163.
   Google Scholar
• Perry R, Terry R, Watson LK, Ernst E. 2012. Is lavender an anxiolytic drug? A systematic review of randomised clinical trials. Phytomedicine 19:825–835.
   Google Scholar
• Petursson H. 1994. The benzodiazepine withdrawal syndrome. Addiction 89:1455–1459.
   PubMed Web of Science ®Google Scholar
• Pincus HA, Davis WW, McQueen LE. 1999. ‘Subthreshold’ mental disorders. A review and synthesis of studies on minor depression and other ‘brand names’.Br J Psychiatry 174:288–296.
   PubMed Web of Science ®Google Scholar
• Rickels K, Garcia-Espana F, Mandos LA, Case GW. 2008. Physician Withdrawal Checklist (PWC-20). J Clin Psychopharmacol 28:447–451.
   PubMed Web of Science ®Google Scholar
• Setzer WN. 2009. Essential oils and anxiolytic aromatherapy. Nat Prod Commun 4:1305–1316.
   PubMed Web of Science ®Google Scholar
• Uehleke B, Schaper S, Dienel A, Schläfke S, Stange R. 2012. Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder. Phytomedicine 19:665–671.
   Google Scholar
• Volz HP, Gastpar M, Kasper S, Möller HJ, Müller WE. 2011. Subsyndromale Angststörungen: Definition, Messparameter, Epidemiologie. J Neurol Neurochir Psychiatr 12:162–167.
   Google Scholar
• Ware JE Jr, Sherbourne CD. 1992. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483.
   Google Scholar
• Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. 2011. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuro psychopharmacol 21:655–679.
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J. 2002. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63:24–34.
   PubMed Web of Science ®Google Scholar
• Woelk H, Schläfke S. 2010. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine 17:94–99.
   PubMed Web of Science ®Google Scholar
• Zung WW. 1971. A rating instrument for anxiety disorders. Psychosomatics 12:371–379.
   PubMed Web of Science ®Google Scholar